Immunic (NASDAQ:IMUX) Coverage Initiated by Analysts at William Blair

William Blair started coverage on shares of Immunic (NASDAQ:IMUX) in a research report released on Tuesday, Marketbeat reports. The firm issued an outperform rating on the stock. William Blair also issued estimates for Immunic’s FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.

A number of other equities analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Immunic in a research report on Friday, February 21st. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Wednesday, February 26th. Finally, StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Immunic has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Trading Up 3.3 %

Immunic stock opened at $1.24 on Tuesday. The firm has a market cap of $111.70 million, a price-to-earnings ratio of -1.01 and a beta of 1.89. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The stock has a fifty day simple moving average of $1.08 and a two-hundred day simple moving average of $1.21.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Invesco Ltd. bought a new position in Immunic during the fourth quarter valued at $37,000. Virtu Financial LLC bought a new stake in shares of Immunic in the third quarter valued at about $50,000. HB Wealth Management LLC purchased a new stake in shares of Immunic in the 4th quarter worth approximately $81,000. Barclays PLC purchased a new stake in Immunic during the fourth quarter worth $84,000. Finally, Jane Street Group LLC lifted its stake in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.